Pirtobrutinib Related Products


SynZeal is a leading innovator in pharmaceutical reference standards. We supply high-quality Reference Standards of Pirtobrutinib, pharmacopeial and non-pharmacopeial Pirtobrutinib impurities, metabolites, stable isotope products, and nitrosamines (N-NO products). Pirtobrutinib impurities reference standards are useful in pharmaceutical research. They are useful in product development, ANDA and DMF filing, quality control (QC), method validation, and stability studies. It is also useful in the identification of unknown impurities and the assessment of genotoxic potential.

Pirtobrutinib-related products are thoroughly characterized. Pirtobrutinib products are supplied with detailed COA & analytical data meeting regulatory compliance. We can also provide EP/USP traceable standards based on your requirements. The supplied products are re-tested at regular intervals.

(R)-Pirtobrutinib

SZ目录编号:: SZ-P208002
CAS 号: 2101700-14-3
分子式: C22H21F4N5O3
分子量: 479.4
投资状态: Custom Synthesis

Pirtobrutinib

SZ目录编号:: SZ-P208001
CAS 号: 2101700-15-4
分子式: C22H21F4N5O3
分子量: 479.4
投资状态: Custom Synthesis

Pirtobrutinib Impurity 1

SZ目录编号:: SZ-P208003
CAS 号: 1453472-99-5
分子式: C10H9F3N2O
分子量: 230.2
投资状态: Custom Synthesis

Pirtobrutinib Impurity 2

SZ目录编号:: SZ-P208004
CAS 号: 1571888-11-3
分子式: C16H14FNO4
分子量: 303.3
投资状态: Custom Synthesis

Pirtobrutinib Impurity 3

SZ目录编号:: SZ-P208005
CAS 号: 1453473-00-1
分子式: C10H11F3N2O
分子量: 232.2
投资状态: Custom Synthesis

Pirtobrutinib Impurity 4

SZ目录编号:: SZ-P208006
CAS 号: 2764851-28-5
分子式: C16H13ClFNO3
分子量: 321.7
投资状态: Custom Synthesis

Pirtobrutinib Impurity 5

SZ目录编号:: SZ-P208007
CAS 号: 2642629-19-2
分子式: C19H14FN3O3
分子量: 351.3
投资状态: Custom Synthesis

Pirtobrutinib Impurity 6

SZ目录编号:: SZ-P208008
CAS 号: 2764851-04-7
分子式: C20H16FN3O3
分子量: 365.4
投资状态: Custom Synthesis

Pirtobrutinib Nitrile Impurity

SZ目录编号:: SZ-P208009
CAS 号: 2642629-21-6
分子式: C22H19F4N5O2
分子量: 461.4
投资状态: Custom Synthesis

Racemic Pirtobrutinib

SZ目录编号:: SZ-P208010
CAS 号: 2101699-71-0
分子式: C22H21F4N5O3
分子量: 479.4
投资状态: Custom Synthesis
categories